Clinical Trials Directory

Trials / Terminated

TerminatedNCT06824870

Exploratory Study Evaluating the Effects of Dermo-cosmetic RV5026B Applied for 2 Months in Adults With Erythrocouperosis

Exploratory Study Evaluating the Effects of RV5026B Dermo-cosmetic Treatment ET1732 Formula Applied for 2 Months in Adult Subjects With Erythrocouperosis Associated With Pityriasis Folliculorum.

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
28 (actual)
Sponsor
Pierre Fabre Dermo Cosmetique · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This exploratory study aims to evaluate the effects of the test product RV5026B - ET1732 on erythema, as well as on the sensations of discomfort and relief perceived in subjects with erythrocouperose and associated pityriasis folliculorum. We wish to evaluate: * firstly the test product alone in order to quantify the effects on the signs \& symptoms on the entire face, * then the contribution of the test product in addition to a reference topical treatment. The test product RV5026B - ET1732 was developed to: * Reduce redness, even if it has already set in, and help limit its reappearance * Soothe the sensations of heating and discomfort associated

Conditions

Interventions

TypeNameDescription
OTHERRV5026B - ET1732 - Period 1Period 1 (1 month): The tested product RV5026B - ET1732 will be applied twice a-day on full-face The product sould be applied in sufficient quantity to cover the application area.
DRUGreference topical product - Period 2Period 2 (1 month) : the reference topical product, prescribed by the investigator will applied each evening on the whole face.
OTHERRV5026B - ET1732 - Period 2Period 2 (1 month) : The tested product RV5026B - ET1732 will be applied twice a-day on randomised half-face. The evening application will be done 15 minutes after the application of the reference treatment. Hands must be washed between the application of the 2 products.

Timeline

Start date
2023-10-20
Primary completion
2025-02-20
Completion
2025-02-20
First posted
2025-02-13
Last updated
2025-04-08

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT06824870. Inclusion in this directory is not an endorsement.